Evotec Q1 Earnings Call Highlights

1 hour ago 1

MarketBeat

Wed, May 6, 2026 astatine 10:54 AM CDT 7 min read

Evotec logo

Key Points

Evotec reported Q1 gross of EUR 156.6 million (down 21.7% YoY) and adjusted EBITDA of negative EUR 21.9 million, with absorption citing EUR 10.2 million of FX headwinds, the non‑recurrence of a $25 million Sandoz licence payment, and softness successful find request (revenues would beryllium down ~6% excluding FX and the Sandoz payment).
The institution reaffirmed full‑year 2026 guidance of EUR 700–780 million successful gross (or EUR 730–810 million astatine changeless currency) and EUR 0–40 million adjusted EBITDA, saying show should amended and beryllium weighted to the 2nd fractional arsenic milestones and D&PD marketplace conditions recover.
Evotec moved its “Horizon” translation into implementation, booked EUR 75 million of reorganization provisions successful Q1, plans to exit the Framingham site, expects unit adjustments starting Q3 2026, and targets ~EUR 75 million of structural run‑rate savings by end‑2027 (20–30% to materialize successful 2026).
Interested successful Evotec AG? Here are 5 stocks we similar better.

Why These 3 Large Caps Are Bucking the August Slump

Evotec (NASDAQ:EVO) reported first-quarter 2026 results that absorption said were shaped by a pugnacious year-over-year comparison, continued softness successful aboriginal cause find demand, and overseas speech headwinds, portion the institution began implementing its “Horizon” concern translation program and reaffirmed full-year guidance.

Q1 results: gross diminution tied to prior-year one-off and FX headwinds

Group gross successful the archetypal 4th totaled EUR 156.6 million, down 21.7% from the prior-year period, Chief Financial Officer Claire Hinshelwood said. On a constant-currency basis, gross decreased 16.6% to EUR 166.9 million. Adjusted radical EBITDA was negative EUR 21.9 million, compared with EUR 3.1 million a twelvemonth earlier (or negative EUR 18.9 million astatine changeless speech rates).

→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

Hinshelwood attributed the year-over-year gross alteration chiefly to 3 factors:

Negative overseas speech effects of EUR 10.2 million, driven chiefly by the U.S. dollar and British pound.
Non-recurrence of a $25 cardinal (EUR 23.1 million) Sandoz licence payment recorded successful Q1 2025.
Continued softness successful demand wrong Discovery & Preclinical Development (D&PD), reflecting a challenging marketplace environment.

Excluding some FX effects and the non-recurring Sandoz license, Hinshelwood said group revenues declined 6%, which she described arsenic a “significantly much moderate” underlying alteration than the reported header decline.